Navigation Links
Studying marrow, URMC researchers accelerate blood stem cells
Date:12/5/2012

University of Rochester Medical Center scientists are testing a new approach to speed a patient's recovery of blood counts during a vulnerable period after a stem-cell transplant, according to a study published in the journal Stem Cells.

Laura M. Calvi, M.D., and Rebecca L. Porter, an M.D./Ph.D. student in Calvi's lab, reported that prostaglandin E2 (PGE2), a drug previously used to treat stomach ulcers, boosts blood production following an assault on the bone marrow from radiation or chemotherapy. Although their study was done in mice, Calvi believes it has significance for patients in the future.

"Our research suggests exciting potential to remedy myelosuppression," said Calvi, an associate professor of Medicine at URMC, with a special interest in endocrine/metabolism and the way blood stem cells behave. "During the first six weeks or so after a transplant, patients can easily acquire serious infections due to low blood counts. It's during this window that we're investigating new opportunities for replenishing cells in the bone marrow, and understanding the mechanisms by which this occurs."

Stem cell transplants, also known as bone marrow transplants or peripheral blood transplants, can be life-saving therapies for people with leukemia, other blood cancers, or blood disorders. The James P. Wilmot Cancer Center at URMC performs about 120 transplants a year, making it the largest program in western New York.

Blood stem cells mostly live in the bone marrow (spongy center of bones) where they divide or stay quiet, mature, and then enter the blood stream, or die. Many things influence the behavioral choices of these cells. And when leukemia, certain types of lymphoma, or injury from chemo and radiation destroys blood stem cells, a transplant offers a fresh replacement.

However, wiping out blood cells (healthy cells and cancer) during the transplant process also presents grave risks for the patient. Transplant success is partly determined by whether the body can remake adequate numbers of new hematopoietic stem cells by spurring them from their usual, quiet state.

Calvi's research discovered that early treatment with PGE2 not only accelerated blood cell recovery, but protected the surrounding microenvironment to stimulate production of the newly transplanted cells. In fact, one of the most promising aspects of the research was the observed activity in the marrow microenvironment, she said.

Prostaglandin is a hormone normally produced in the body, and during radiation or chemotherapy the hormone rushes in to mediate the inflammatory response. Prostaglandin usually remains elevated for about six days. During this time, the bone marrow begins to recover slowly on its own. However, Calvi's research also showed that feeding the PGE2 drug compound to mice seemed to offer an additional benefit during this time, by changing the marrow's environment to make it more supportive of faster and better blood cell production.

In fact, early treatment with PGE2 expanded blood cells in several different ways: Not only did the drug increase proliferation of new, healthy blood cells, but it slowed the death of cells being rapidly killed off during the response to radiation injury.

"Having the ability to manipulate the function of hematopoietic stem cells in this context offers new and meaningful approaches for the clinic," Calvi said. "Patients face very serious consequences when the bone marrow doesn't make enough platelets and other blood cells, and few options are currently available to aid the recovery."
'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Does Studying for Law School Test Boost Your Brain?
2. By studying animal health, researchers find improved ways for developing, testing cancer therapies
3. Studying couples to improve health, better relationships
4. UNM Cancer Center researchers study new target for breast cancer
5. Barrow researchers successfully destroy brain tumor cells
6. Western University researchers make breakthrough in arthritis research
7. Researchers report first success of targeted therapy in most common non-small cell lung cancer
8. USC, Oxford researchers find high fructose corn syrup-global prevalence of diabetes link
9. Researchers study cry acoustics to determine risk for autism
10. Researchers explore social media as preventative method for infectious diseases
11. New mechanism for cancer progression discovered by UNC and Harvard researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology: